

Date: June 18, 2026

To,
Corporate Relationship Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Company Code: QLINE

Sub: Press Release on Financial Result for half and Financial Year ended 31.03.2026

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith a Press Release on results for half and Financial Year ended 31.03.2026. A press Release is also enclosed with this letter. The above information is also available on the Company's website: www.qlinebiotech.com.

You are requested to take the note of the same.

Thanking you

For Q-Line Biotech Limited



Saurabh Garg
Managing Director
DIN: 02891621

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023

Delhi Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407

E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528

Q-LINE BIOTECH LIMITED

Financial Results — Half Year & Full Year ended March 31, 2026

FY26 Profit after Tax up 56.75% Y-o-Y; Revenue +9.13%, EBITDA +38.97%

| | | | |
|----------------|----------------|----------------|---------------|
| +9.13% | +38.97% | +42.23% | +56.7% |
| REVENUE | EBITDA | PBT | PAT |
| FY26 Y-o-Y | FY26 Y-o-Y | FY26 Y-o-Y | FY26 Y-o-Y |

Q-Line Biotech Limited, a leading manufacturer of diagnostic test kits, reagents and laboratory equipment in India, today announced its audited financial results for the half year and year ended March 31, 2026. Headquartered in Lucknow and promoted by the Garg family, which brings over 31 years of experience in the diagnostics industry, the Company serves diagnostic laboratories and hospitals across 26 states through its extensive distribution network. The Company delivered a strong performance during the year, driven by sustained demand for its products, expanding market presence and continued focus on operational excellence.

The Board of Directors, at its meeting held on June,17 2026, approved the financial results for the period under review.

Financial Performance Summary

H2 Consolidated FY26 & FY26 (Rs. in lakhs)

| Particulars | H2 FY26 | H1 FY26 | H2 FY25 | FY26 | FY25 | FY26 Y-o-Y |
|-----------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|----------------|
| Total Revenue* | 19,793.76 | 14,379.81 | 21654.6 | 34173.57 | 31314.37 | +9.13% |
| EBITDA** | 6,207.84 | 3,596.70 | 4,481.56 | 9,804.54 | 7,055.05 | +38.97% |
| Profit Before Tax*** | 4,729.57 | 2,624.58 | 3,917.40 | 7,354.15 | 5,170.75 | +42.23% |
| Profit After Tax*** | 3,539.72 | 2,131.62 | 2,347.15 | 5,671.34 | 3,618.08 | +56.75% |

*Total Revenue excluding Other Income.

**EBITDA = Profit before Tax before extraordinary items and prior period expenses+ Finance Cost + Depreciation-Less Other Income

*** PBT & PAT Excluding Extraordinary Items

H2 FY26 Momentum — A Step-Change in Profitability

Performance accelerated meaningfully in H2 FY26, with revenue and profitability scaling sharply on YOY basis — underscoring the strength of order execution and operating leverage.

| Particulars | H1 v/s H2 of Fiscal 26 | Fiscal 26 V/s Fiscal 25 Growth | |
|-------------------|------------------------|--------------------------------|-------------------------|
| Total Revenue | +37.65% | +9.13% | {of Total Revenue} |
| EBITDA | +72.60% | +38.97% | EBITDA Margin 28.69% |
| Profit Before Tax | +80.20% | +42.23% | PBT Margin 21.52% |
| Profit After Tax | +66.06% | +56.75% | PAT Margin 16.60% |

Key Financial Highlights — FY26 vs FY25

- Total Revenue grew **9.13% Y-o-Y** to ₹341.73 crore — reflecting strong business momentum and sustained demand.
- EBITDA expanded **38.97% Y-o-Y** to ₹98.04 crore, with EBITDA margin strengthening to 28.69% (FY25: 22.53%).
- Profits before Tax surged **42.23% Y-o-Y** to ₹73.54 crore — a clear demonstration of operating leverage.
- Profit after Tax surged, up **56.75% Y-o-Y** to ₹56.71 crore
- Reagents and diagnostic kits account for approximately 69% of the Company's revenue, providing a strong recurring revenue base due to their consumable nature and regular demand from diagnostic laboratories and healthcare institutions.
- The Company has significantly enhanced its profitability profile, with EBITDA margins increasing from approximately 22% to around 28%. This improvement has been primarily driven by nearly **70%** growth in the sales of domestically manufactured reagents, which carry higher margins, along with improved operating efficiencies, a favorable product mix, and disciplined cost management.
- The Company has significantly reduced its dependence on imports by localizing manufacturing operations. more than 50% of its laboratory equipment is now manufactured in India through strategic collaborations with European technology partners, strengthening margins, improving supply-chain resilience, and supporting sustainable long-term growth.

Half-Year Performance — H2 FY26 vs H1 FY26

- Revenue grew **37.65% H-o-H** to ₹ 197.93 crore — reflecting healthy business momentum and continued demand.
- EBITDA increased **72.6% H-o-H** to ₹ 62.07 crore driven by improved operating leverage and enhanced operational efficiencies.
- Profits before Tax surged, up **80.2% H-o-H** to ₹ 47.29 crore.
- Profit after Tax surged, up **66.06% H-o-H** to ₹ 35.40 crore

Key Business Developments

1. **Manufacturing Expansion:** The Company has obtained product licenses for five products at its new manufacturing facility, Unit 4 with additional licenses currently under various stages of approval. With regulatory approvals progressing as planned, the Company expects to commence full-scale commercial production of Clinical Chemistry Reagents at the facility by Q2 FY27, further strengthening its manufacturing capabilities and supporting future growth.
2. **Digital Transformation Initiative:** The Company has commenced the implementation of a new ERP platform aimed at enhancing operational controls, business process automation, and data-driven decision-making. The Functional Requirement Documents (FRDs) have been finalized, and the project is progressing as planned, with full implementation targeted at the end of FY27. **Strengthening Governance Framework:**
3. The Company has engaged PwC to assist in enhancing its Internal Financial Controls (IFC) and Internal Controls over Financial Reporting (ICFR). This initiative is aimed at strengthening governance practices, improving risk management processes, and establishing a robust control environment to support the Company's next phase of growth as a listed entity.
4. **International Expansion:** As part of its global growth strategy, the Company appointed an International Business Manager based in Dubai to accelerate business development and strengthen its export network. This initiative has already yielded positive results, contributing export sales of approximately ₹ 1.18 Cr during the year. Further, the Company has executed distributor agreements across 7–8 countries as of March 2026, laying the foundation for a broader international presence. Leveraging these strategic partnerships and an expanding global distribution network, the Company expects its export revenues to grow to nearly 5X in FY27.
5. We intend to initiate CDMO operations through the manufacture of Selectra Pro M and Microlab 300 instruments. Under our exclusive technical collaboration arrangement, these instruments will be exported to the principal company, thereby enabling us to leverage our manufacturing capabilities for international markets in addition to serving the Indian market
6. We have exclusive technical collaboration agreements for Indian markets with Vital Scientific and Boule Sweden AB for the manufacture and commercialization of certain instruments and reagents, providing us access to proven technologies and supporting our product portfolio expansion.

Management Commentary

Saurabh Garg, MD & Chairman, Q Line Biotech:

FY26 has been a transformative year for Q-Line Biotech Limited. The successful capitalization of our largest manufacturing facility in Lucknow marks a significant milestone in our journey and substantially strengthens our manufacturing capabilities. During the year, sales of manufactured reagents increased by nearly 70%, reflecting our strategic focus on expanding in-house manufacturing, improving value addition, and reducing dependence on traded products.

We also achieved a key milestone in our instruments division, reaching an installed base of over 1,550 Selectra Pro M Fully Automatic Biochemistry Analysers, our flagship equipment product, whose manufacturing commenced in December 2023. In addition, we successfully commercialized our Electrolyte Analyzer and are on track to launch the Micro lab 300 by Q2 FY27, further expanding and diversifying our diagnostic instruments portfolio.

These achievements have strengthened our profitability profile, improved operating leverage, and reinforced our position in the diagnostics ecosystem. As we continue to invest in manufacturing, innovation, and product development, we remain well-positioned to capitalize on the growing demand for high-quality diagnostic solutions and create long-term value for all stakeholders.”

FY27 Guidance

| | |
|---|---|
| <p>Revenue Growth Target</p> <p>~30 to 35% Y-o-Y in FY27</p> | <p>Profitability Target</p> <p>Corresponding EBITDA margin</p> |
|---|---|

FY27 growth will be supported by IPO proceeds allocated towards working capital. These funds will be utilized to expand our sales force, deepen geographic penetration, and increase the installed base of instruments. A larger installed base is expected to drive recurring reagent sales, while CDMO and export operations are also expected to contribute to overall revenue growth.

About Q-Line Biotech Limited

Q-Line Biotech Limited is engaged in the development, manufacturing, and marketing of diagnostic reagents, kits, point-of-care (POC) devices, consumables, and in-vitro diagnostic (IVD) equipment. Since 2016, the Company has been serving diagnostic laboratories, hospitals, and medical colleges across India through a direct and distributor-led network.

Over the past 12 years, the Company has established a strong presence in the IVD industry through its manufacturing capabilities, research & development expertise, and quality-focused approach. Its product portfolio spans key diagnostic segments, including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and POC Devices & Rapid Tests.

The Company further strengthened its capabilities during the COVID-19 pandemic by developing and commercializing a range of testing solutions, including RT-PCR Kits, RNA Extraction Kits, and VTM Kits, leveraging both in-house R&D and strategic technical collaborations.

Safe Harbour

This release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially. Q-LINE BIOTECH undertakes no obligation to update or revise any forward-looking statements except as required by law.